{
  "hash": "4b855b5dc28a9424aecf0c45aa7b7023",
  "result": {
    "markdown": "---\ntitle: \"Sub-teams\"\ndate-modified: last-modified\noutput: \n  rmarkdown::html_document:\n    highlight: pygments\n    number_sections: yes\n    self_contained: yes\n    toc: yes\n    toc_depth: 3\n    toc_float: yes\n---\n\n\n\n::: {.cell}\n\n:::\n\n## Real World Evidence/Real World Data (RWE/RWD)\n\n**Lead**: Shihua Wen (Novartis)\n\n**Objective**: NA\n\n::: {.cell-output-display}\n|Firstname |Lastname |Institution |\n|:---------|:--------|:-----------|\n|Zhenzhen  |Xu       |FDA         |\n|Khadija   |Rantell  |MHRA        |\n|Lina      |Yang     |Novartis    |\n|Shihua    |Wen      |Novartis    |\n|Yeonhee   |NA       |NA          |\n:::\n\n::: {.cell}\n\n:::\n\n## Estimand\n\n**Lead**: Nicolas Ballarini (Novartis)\n\n**Objective**: The objective of this WG is to promote the concept of estimands and establish a harmonized estimand framework for the clinical development of Cell and Gene Therapies (CGT). Specifically, the WGâ€™s aim is to identify and address the unique challenges posed by intercurrent events in CGT development, and formulate appropriate strategies for their handling.\n\n::: {.cell-output-display}\n|Firstname  |Lastname  |Institution |\n|:----------|:---------|:-----------|\n|Yiran      |Hu        |Abbvie      |\n|Alessandro |Previtali |Bms         |\n|Khadija    |Rantell   |MHRA        |\n|Nicolas    |Ballarini |Novartis    |\n|Shihua     |Wen       |Novartis    |\n|Avery      |McIntosh  |Pfizer      |\n:::\n\n::: {.cell}\n\n:::\n\n## Dose Finding\n\n**Lead**: Rong Liu (Regeneron)\n\n**Objective**: NA\n\n::: {.cell-output-display}\n|Firstname |Lastname        |Institution |\n|:---------|:---------------|:-----------|\n|Daniel    |Li              |Bms         |\n|Revathi   |Ananthakrishnan |Bms         |\n|Ally      |He              |Crisprtx    |\n|Andrew    |Lewandowski     |Novartis    |\n|Bambang   |Adiwijaya       |Novartis    |\n|Rong      |Liu             |Regeneron   |\n:::\n\n::: {.cell}\n\n:::\n\n## CMC\n\n**Lead**: Alan Chiang (Lyell)\n\n**Objective**: To identify key CMC challenges in CGT development and to serve as key opinion leaders in CGT CMC within biopharmaceutical communities\n\n::: {.cell-output-display}\n|Firstname |Lastname |Institution |\n|:---------|:--------|:-----------|\n|Sangwook  |Choi     |Bms         |\n|Bill      |Pikounis |JNJ         |\n|Jose      |Ramirez  |Kitepharma  |\n|Alan      |Chiang   |Lyell       |\n|Lina      |Yang     |Novartis    |\n:::\n\n::: {.cell}\n\n:::\n\n## Outreach\n\n**Lead**: Patricia Anderson (Iconplc)\n\n**Objective**: NA\n\n::: {.cell-output-display}\n|Firstname |Lastname        |Institution |\n|:---------|:---------------|:-----------|\n|Revathi   |Ananthakrishnan |Bms         |\n|Patricia  |Anderson        |Iconplc     |\n|Alan      |Chiang          |Lyell       |\n|Khadija   |Rantell         |MHRA        |\n|Nicolas   |Ballarini       |Novartis    |\n|Shihua    |Wen             |Novartis    |\n:::\n\n::: {.cell}\n\n:::\n\n## Trial Design Subteam\n\n**Lead**: Weidong Zang (Sana)\n\n**Objective**: NA\n\n::: {.cell-output-display}\n|Firstname |Lastname        |Institution |\n|:---------|:---------------|:-----------|\n|Daniel    |Li              |Bms         |\n|Revathi   |Ananthakrishnan |Bms         |\n|Zhenzhen  |Xu              |FDA         |\n|Patricia  |Anderson        |Iconplc     |\n|Evgeny    |Degtyarev       |Novartis    |\n|Nicolas   |Ballarini       |Novartis    |\n:::\n\n::: {.cell}\n\n:::\n\n## LTFU\n\n**Lead**: Khadija Rantell (MHRA)\n\n**Objective**: NA\n\n::: {.cell-output-display}\n|Firstname |Lastname |Institution |\n|:---------|:--------|:-----------|\n|Patricia  |Anderson |Iconplc     |\n|Alan      |Chiang   |Lyell       |\n|Alex      |Sverdlov |Novartis    |\n|Shihua    |Wen      |Novartis    |\n:::\n",
    "supporting": [
      "subteams_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}